Objective
Aortic valve stenosis is a progressive inflammatory disorder with poor prognosis if left untreated. Currently the only available treatment is invasive surgical replacement of the valve, therefore new therapeutic strategies are needed. Resolution of inflammation is an active process orchestrated by endogenous specialized proresolving lipid mediators (SPM). These include the resolvins that actively promote catabasis via their potent actions in anti-inflammation, proresolution, tissue regeneration and pain reduction. Recently the complete stereochemistry of resolvin D3 (RvD3) was established. Given its highly potent anti-inflammatory and proresolving actions in murine models and with human cells its role and actions in aortic stenosis (AS) remains to be uncovered. Thus, a goal of this proposal is to elucidate endogenous resolution programs in human aortic valves and define the role and action of RvD3 in AS and calcification. To address this the candidate will employ LC-MS-MS based LM metabololipidomics combined with clinically relevant parameters as well as biochemical and cellular assessments in samples from AS patients. In addition, RvD3 will be used as treatment in a novel preclinical model of murine AS. Implementation of the proposed project will maintain and enhance the candidate’s position at the forefront in the field of resolution biochemistry with advances into valvular pathology. Unraveling the role of RvD3 and resolution programs in aortic inflammation and resolution may enhance current understanding of the molecular mechanism contributing to chronic cardiovascular inflammation and introduce a novel concept for the pathology AS. Furthermore, it may lead to novel therapeutic strategies with a potential to slow or halt the hemodynamic progression of stenosis via turning on resolution programs.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences health sciences inflammatory diseases
- medical and health sciences clinical medicine cardiology cardiovascular diseases arteriosclerosis
- natural sciences biological sciences biochemistry biomolecules lipids
- medical and health sciences basic medicine pathology
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF-EF-RI - RI – Reintegration panel
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2014
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
171 77 STOCKHOLM
Sweden
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.